Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rostagno, R."'
Autor:
Luca Mologni, Roberta Rostagno, Michela Viltadi, Vera Magistroni, Rocco Piazza, Carlo Gambacorti-Passerini, Daniel L. Flynn, Sara Redaelli, Monica Ceccon
BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase domain (KD) mutations represent the most frequently described mechanism of resistance to the treatment with tyrosine kinase inhibitors (TKI) in patients with chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f22478145c4e1c6d473505e7a24b59a
http://hdl.handle.net/10281/53754
http://hdl.handle.net/10281/53754
Autor:
Leonardo Scapozza, Elisa Sala, Thomas Kuoni, Luca Mologni, Roberta Rostagno, Carlo Gambacorti-Passerini, Loredana Cleris, Barbara Riva, Jenny Bain, Sara Redaelli, Miriam Puttini, Franca Formelli, Sara Cazzaniga
Thyroid neoplasia is frequently associated with rearranged during transfection (RET) proto-oncogene mutations that cause hyperactivation of RET kinase activity. Selective inhibition of RET-mediated signaling should lead to an efficacious therapy. SU5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e88d6dcc4618de02d1c96cff2d18e3
http://hdl.handle.net/10281/545
http://hdl.handle.net/10281/545
Autor:
Roberta Rostagno, Rocco Piazza, Leonardo Scapozza, Carlo Gambacorti-Passerini, Annamaria Galietta, Rosalind H. Gunby
Publikováno v:
The Lancet. Oncology. 4(2)
Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-positive (Ph-positive) leukaemias, gastrointestinal stromal tumours, an